Development asset linked to Beam Therapeutics in public FDA and regional records.
biotech · Sleep · T-Cell Acute Lymphoblastic Leukemia/Lymphoma · BEAM
Beam Therapeutics
Beam Therapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2017 Founded
573 Employees
Public company Type
BEAM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 573
- Programs
- 10
- Drugs
- 14
- Patents
- 14
Beam Therapeutics pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Beam Therapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Beam Therapeutics's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
Development asset linked to Beam Therapeutics in public FDA and regional records.
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Beam Therapeutics's portfolio.
-
Development asset linked to Beam Therapeutics in public FDA and regional records.
-
Development asset linked to Beam Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Beam Therapeutics in public FDA and regional records.
-
Development asset linked to Beam Therapeutics in public FDA and regional records.